证券代码：600223 证券简称：福瑞达 编号：临 2025-030 鲁商福瑞达医药股份有限公司 关于转让全资子公司山东鲁商银座商业管理有限公司 100%股权暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 为聚焦主业发展，持续提升公司运行质量，鲁商福瑞达医药股份有限公司 （以下简称"公司"）拟将持有的山东鲁商银座商业管理有限公司（以下简称"银 座商管"）100%股权转让给鲁商福瑞达健康投资有限公司，交易价款依据评估值 确定为8,840.28万元。本次交易完成后，公司将不再持有银座商管的股权。 本次交易方鲁商福瑞达健康投资有限公司与公司为同受山东省商业集团 有限公司控制的公司，故本次交易构成关联交易。 本次交易未构成重大资产重组。 公司不存在为银座商管提供担保、委托理财，以及该公司占用上市公司资 金等方面的情况。 至本次关联交易为止，过去12个月内公司与同一关联人或与不同关联人之 间交易类别相同的关联交易未达到公司最近一期经审计净资产绝对值5%以上（不 含已履行相关程序的关联交易），本次关联 ...

法律意见书 国浩律师（济南）事务所 关于鲁商福瑞达医药股份有限公司 2025 年第一次临时股东会 之 济南市龙奥西路 1 号银丰财富广场 C 座 19、20、25 层 邮编：250014 19th-20th、25thFloor,BlockC,YinfengFortunePlaza,No.1Long'aoWestRoad,Jinan 电话/Tel:+8653186112118 传真/Fax:+8653186110945 网址/Website:http://www.grandall.com.cn 二〇二五年十月 国浩律师（济南）事务所（以下简称"本所"）接受鲁商福瑞达医药股份有 限公司（以下简称"福瑞达"或"公司"）的委托，指派本所律师林泽若明、张 灵君（以下简称"本所律师"）出席福瑞达 2025 年第一次临时股东会（以下简 称"本次股东会"），并出具本法律意见书。 为出具本法律意见书，本所律师出席了本次股东会，并依据《中华人民共和 国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简 称"《证券法》"）、《律师事务所从事证券法律业务管理办法》和《律师事务 所证券法律业务执业规则》等法律法规及规 ...

证券代码：600223 证券简称：福瑞达 公告编号：2025-029 鲁商福瑞达医药股份有限公司 2025年第一次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、会议召开和出席情况 （一）股东会召开的时间：2025 年 10 月 10 日 （二）股东会召开的地点：山东省济南市高新区新泺大街 888 号公司会议室 （三）出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 604 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 577,748,396 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份 | | | 总数的比例（%） | 56.8331 | （四）表决方式是否符合《公司法》及《公司章程》的规定，股东会主持情况等。 本次股东会由公司董事会召集，会议由贾庆文先生主持。本次股东会采取现场投 票和网络投票相结合的方式进行表决。本次股东会的召集、召开及表决方 ...

独立董事：宿玉海、朱德胜 2025 年 10 月 11 日 鲁商福瑞达医药股份有限公司 第十二届董事会独立董事专门会议决议 鲁商福瑞达医药股份有限公司（以下简称"公司"）第十二届董事会独立董事专 门会议于 2025 年 9 月 30 日发出通知，并于 2025 年 10 月 9 日在公司会议室召开。 经过半数独立董事共同推举，本次会议由独立董事宿玉海召集和主持，本次会议应 参会独立董事 2 名，实际参加表决的独立董事 2 名，本次会议的召集、召开符合《中 华人民共和国公司法》《上市公司独立董事管理办法》《公司章程》《独立董事工作制 度》等有关规定，会议合法有效。 经参会独立董事审议，一致通过《关于转让全资子公司山东鲁商银座商业管理 有限公司 100%股权暨关联交易的议案》，独立董事认为：本次关联交易遵循了客观、 公正的原则，估值合理、价格公允，符合《公司法》《证券法》《上海证券交易所股 票上市规则》等法律法规和《公司章程》的有关规定，本次转让山东鲁商银座商业 管理有限公司 100%股权，有利于公司进一步优化资源配置，聚焦主业，符合公司战 略规划和发展需要，不存在损害公司及其他股东特别是中、小股东利益的情形。同 ...

Core Insights - The cosmetics sector experienced a rise of 1.51% on October 10, with Shuiyang Co. leading the gains [1] - The Shanghai Composite Index closed at 3897.03, down 0.94%, while the Shenzhen Component Index closed at 13355.42, down 2.7% [1] Company Performance - Shuiyang Co. (300740) closed at 23.93, up 8.72%, with a trading volume of 397,000 shares and a transaction value of 931 million yuan [1] - Jiahen Jiahua (300955) closed at 37.76, up 7.95%, with a trading volume of 119,800 shares and a transaction value of 438 million yuan [1] - Lafang Jiahua (603630) closed at 23.80, up 3.30%, with a trading volume of 73,600 shares and a transaction value of 17.5 million yuan [1] - Other notable performers include Bawi Co. (920123) up 2.45%, Shanghai Jahwa (600315) up 1.91%, and Jingsheng New Materials (300849) up 1.40% [1] Fund Flow Analysis - The cosmetics sector saw a net inflow of 96.14 million yuan from institutional investors, while retail investors experienced a net outflow of 98.20 million yuan [1] - Shuiyang Co. had a net inflow of 43.09 million yuan from institutional investors, but a net outflow of 33.48 million yuan from retail investors [2] - Jiahen Jiahua recorded a net inflow of 33.03 million yuan from institutional investors, with a significant net outflow of 67.04 million yuan from retail investors [2]

Investment Rating - The report maintains a "Recommend" rating for the company with a target price of 10.11 yuan [2][9]. Core Views - The company is experiencing a phase of performance pressure, with a 7.05% year-on-year decline in revenue and a 15.16% drop in net profit for the first half of 2025. The revenue for 25H1 was 1.79 billion yuan, and the net profit was 108 million yuan [2][9]. - The company is undergoing strategic adjustments, particularly in its product lines, with expectations for performance recovery as new products are launched and adjustments take effect [9]. Financial Performance Summary - **2025 Half-Year Performance**: Revenue was 1.79 billion yuan (-7.05% YoY), and net profit was 108 million yuan (-15.16% YoY). The gross margin was 52.3% (+0.5pp YoY), and the net margin was 7.5% (-0.6pp YoY) [2]. - **2025 Q2 Performance**: Revenue was 913 million yuan (-11.7% YoY), and net profit was 57 million yuan (-16.1% YoY). The gross margin was 53.4% (+0.6pp YoY), and the net margin was 7.8% (-0.2pp YoY) [2]. - **Future Financial Projections**: Expected revenues for 2024A, 2025E, 2026E, and 2027E are 3.983 billion, 3.798 billion, 4.189 billion, and 4.598 billion yuan respectively, with corresponding net profits of 244 million, 248 million, 294 million, and 350 million yuan [5][10]. Business Segment Performance - **Cosmetics Segment**: Revenue was 1.094 billion yuan (-7.73% YoY). The "Yilian" brand showed strong growth with a 23.78% increase in revenue to 554 million yuan, driven by successful marketing and product upgrades [9]. - **Raw Materials Segment**: Revenue was 179 million yuan (+4.15% YoY), with a notable increase in high-value products, particularly in hyaluronic acid (HA) sales, which grew by 287.3% YoY [9]. R&D and Innovation - The company continues to invest in R&D, with expenses increasing by 20.60% YoY to 79 million yuan in the first half of 2025. New product launches, including the "transdermal collagen" technology, are expected to drive future growth [9].

Core Insights - The Yilian brand, under Furuida Biological Co., has achieved a brand value assessment exceeding 12 billion yuan, establishing itself as a benchmark in the domestic fragrance and cosmetics industry [2][10] - The brand value assessment utilized a model that integrates international best practices with Chinese market characteristics, focusing on three dimensions: brand benchmark revenue, brand strength index, and brand development index [4] - The assessment involved a comprehensive survey of 30 international brands, 15 domestic listed brands, 115 traditional domestic brands, 30 emerging domestic brands, and 10 domestic time-honored brands [4] Brand Performance - Yilian excelled in key indicators such as revenue scale, research and development capabilities, brand cultural strength, and ESG performance, leading to its brand value recognition of 12 billion yuan [4][10] - The brand's principal, Jiang Liangyan, emphasized the importance of balancing short-term sales growth with long-term brand value, advocating for a transition from "traffic brands" to "value brands" [6] Assessment Framework - The brand value assessment framework serves as a "value declaration," encouraging brands to achieve a harmonious ecosystem beyond just sales and visibility [8] - The framework aims to inspire companies to become respected by consumers and the industry, thereby enhancing the visibility and transmission of good brand values [8] Strategic Direction - Yilian's commitment to a "technology + culture" development philosophy focuses on the hyaluronic acid moisturizing and repair sector, reflecting its strategic achievements in global competition [10] - The brand aims to continue driving innovation and leading the Chinese fragrance and cosmetics industry towards higher value dimensions [10]

Core Insights - Zhao Yan, the richest woman in Shandong, has a net worth of 50 billion, largely attributed to her success in the beauty industry with hyaluronic acid, which has a cost of only 15 yuan but sells for 5000 yuan, highlighting a significant price disparity and consumer willingness to pay for beauty [1][22]. Group 1: Background and Early Career - Zhao Yan graduated from East China Normal University and initially worked as a teacher, a stable job for women at the time, but she sought more adventurous opportunities in business [3]. - In 1987, she decided to leave her teaching position to explore business opportunities in Hainan, which was then a hotspot for entrepreneurs [5]. Group 2: Business Ventures - Zhao Yan's first major business success came from purchasing and repairing faulty refrigerators, which she sold at lower prices, earning 800,000 yuan, a significant amount at the time [9]. - She later ventured into real estate, acquiring land before the property prices surged, and successfully exited the market before the bubble burst, increasing her capital [11]. Group 3: Entry into the Beauty Industry - The pivotal moment in Zhao Yan's career occurred during her MBA studies at Peking University when she learned about hyaluronic acid from a contact at Shandong Pharmaceutical Research Institute [15]. - Recognizing the potential of hyaluronic acid in the beauty market, she invested 12 million yuan for a 50% stake in a company and allocated 200 million yuan for research and marketing, despite skepticism from others [19]. Group 4: Market Impact and Controversies - The rise of the medical beauty trend led to a surge in demand for hyaluronic acid, with 10 million units sold in hospitals across China in 2016, establishing her company as a leading supplier [21]. - Despite her success, Zhao Yan faced criticism for the high markup on her products, with some labeling it as a "tax on intelligence," although the costs involved in production and marketing were substantial [22][24]. - Controversies surrounding her business practices, including allegations of pressuring employees to sell stocks at low prices, have added complexity to her public image [26]. Group 5: Conclusion - Zhao Yan's journey reflects a keen understanding of market demands and the ability to capitalize on emerging trends, transforming a simple raw material into a billion-dollar business [29].

Core Insights - The Chinese fragrance and cosmetics industry is entering a golden era, transitioning from a "cosmetic manufacturing powerhouse" to a "cosmetic manufacturing stronghold" with a focus on high-quality development [2][7] - The total transaction value of cosmetics across all channels reached 702.1 billion yuan from January to August 2025, reflecting a year-on-year growth of 2.53%, indicating a shift towards rational growth and the end of the era of reckless expansion [2] - The industry consensus is shifting from a focus on cash-burning for traffic acquisition to cultivating user value, emphasizing a balanced approach between online and offline channels [2][5] Industry Trends - The 2025 China Fragrance and Cosmetics Industry Annual Conference (2025CAME) highlighted the importance of technology and culture in driving value creation, with a clear shift from marketing-heavy strategies to research and development [4][6] - Domestic brands are increasingly leveraging technology to establish a competitive edge, moving from "ingredient parity" to "patent leadership" [4] - The integration of cultural elements into branding is becoming a key differentiator for Chinese brands in the global market, moving beyond superficial aesthetics to deeper cultural narratives [5] Market Dynamics - The relationship between online and offline channels is evolving into a symbiotic one, where both are essential for success, with a focus on user experience and trust [5] - The industry is facing global competition that emphasizes safety, environmental standards, and ethical considerations, which are becoming the new benchmarks for market entry [6] - The Chinese fragrance and cosmetics industry is transitioning from being a major consumer market to a significant source of innovation and cultural output on the global stage [6][7] Future Outlook - The industry is building a core value system centered on technology, culture, and user value, reflecting a broader shift in the Chinese economy towards innovation-driven growth [7] - Despite challenges such as core technology breakthroughs and international market volatility, the industry is poised for a transformative decade, aiming to showcase Chinese wisdom and Eastern aesthetics globally [7]

Core Insights - Vitamin B12, also known as cobalamin, is essential for human health, playing a critical role in nerve function and preventing pernicious anemia. It is used in the treatment of various diseases such as cerebral hemorrhage, Alzheimer's disease, and acute myelitis. The market demand for Vitamin B12 supplements is increasing due to rising health awareness among consumers. The market size of the cobalamin industry in China is projected to reach 1.4 billion yuan in 2024, representing a year-on-year growth of 6% [1][10]. Industry Overview - Cobalamin, or Vitamin B12, is the only vitamin that contains a metal element. It is a red crystalline powder that is water-soluble and plays multiple indispensable roles in the human body, including maintaining a healthy nervous system and promoting red blood cell production [3][10]. - The primary sources of Vitamin B12 are animal products, with some plant sources like soybeans containing lower amounts. The vitamin is crucial for protein and amino acid synthesis, especially in infants [3]. Market Dynamics - China is a major supplier of Vitamin B12 globally, with significant export volumes. The export quantity of unblended Vitamin B12 and its derivatives is expected to grow from 355.08 tons in 2020 to 498.08 tons by 2024 [10]. - The competition in the cobalamin market is intensifying due to limited market size and high domestic production capacity. Major players include Hebei Huaron, Yuxing Bio, Ningxia Jinyi, and Jiutian Pharmaceutical [10][11]. Production Methods - The cobalamin industry primarily utilizes microbial fermentation methods for production, as chemical synthesis is complex and costly. The fermentation process mainly involves anaerobic fermentation using Propionibacterium and aerobic fermentation using Pseudomonas [8]. Industry Trends - The cobalamin industry is expected to see continuous technological innovation, focusing on refining extraction methods and enhancing product stability. The use of biotechnological advancements will likely lead to higher activity and lower impurity levels in cobalamin products [12]. - There is a trend towards high-end and diversified product offerings to meet varying consumer needs, including specialized products for anemia treatment and a wider range of dosage forms [13]. - The industry is moving towards environmentally sustainable practices, including green sourcing of raw materials and energy-efficient extraction processes [14].